Solventum Corp (SOLV) stock
Close on Nov 11, 2026Market cap $15.09BP/E 99.6Yield –
Solventum Corp saw revenue fall 2.8% to $8.16B over the twelve months to Sep 30, 2026. Operating income fell 79.3% to $454.00M, moving the operating margin from 26.1% to 5.6%. Free cash flow was $0, down 100.0% from a year earlier. At the latest close the market valued the company at $15.09B, 99.6 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $15.09B
- P/E ratio
- 99.6
- Price to sales
- 1.85
- Price to book
- 3.14
- Dividend yield
- –
- Free cash flow yield
- 0.00%
Fundamentals
- Revenue
- $8.16B
- Net income
- $156.00M
- EPS, diluted
- $0.89
- Free cash flow
- $0
- Book value per share
- $28.13
- Diluted shares
- 171M
Trading
- Next earnings
- Feb 25, 2027 (estimated, during market hours)
- Previous close
- $90.08
- Open
- $89.30
- Day's range
- $88.46 – $90.26
- Volume
- 728,320
- Average volume (20 days)
- 1,297,713
- Index membership
- S&P 500 (since Jun 2024), Russell 1000 (since Jun 2024), Russell 3000 (since May 2024)
- Beta (5 years)
- 0.52
- 52-week range
- $62.38 – $94.16
- RSI (14 days)
- 54.2
- Volatility (1 year)
- 30.0%
- Relative volume
- 0.66×
- WACC
- 7.2%
Index membership is inferred from the holdings of funds that track each index (VOO, IVV, SPYM, IWB, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2024, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | SOLV | S&P 500 | Difference | SOLV per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +1.5% | -2.4% | +3.9 pts | ||
| 3 months | +5.4% | -1.2% | +6.5 pts | ||
| Year to date | +11.8% | +12.3% | −0.5 pts | ||
| 1 year | +20.0% | +12.4% | +7.5 pts |
Five years at a glance
Fiscal years 2021 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Solventum filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- News
- Results
- Results
About Solventum
Surgical & Medical Instruments & Apparatus
Solventum Corporation is a global healthcare enterprise that develops, manufactures, and commercializes clinical and technological solutions. The company operates across three core business segments: MedSurg, Dental Solutions, and Health Information Systems. Its MedSurg portfolio encompasses negative pressure wound therapy, dressings, surgical supplies, and infection-prevention devices. The Dental Solutions division delivers restorative materials, cements, and orthodontic equipment covering comprehensive tooth care. Through its Health Information Systems unit, the organization supplies documentation software, automated billing and coding platforms, speech recognition, and data tools. Solventum sells its products and services directly and through partner networks to multidisciplinary hospitals, private clinics, physicians, and dental practitioners.
Company profile, executives and historySolventum stock: common questions
What is Solventum's stock price?
SOLV closed at $88.62 on Nov 11, 2026, down 1.62% on the day. Over the past 52 weeks it traded between $62.38 and $94.16.
What is Solventum's market cap?
Solventum was worth $15.09B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is SOLV's P/E ratio?
SOLV trades at 99.6 times earnings, based on diluted earnings per share of $0.89 over the twelve months to Sep 30, 2026.
How much revenue does Solventum make?
Solventum reported revenue of $8.16B for the twelve months to Sep 30, 2026, down 2.8% from a year earlier.
Does Solventum pay a dividend?
No. Solventum has not paid a cash dividend over the last twelve months.
When does Solventum report earnings next?
Solventum is expected to report Q4 FY2026 results on Feb 25, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has SOLV stock performed over the past year?
Including dividends, SOLV returned +20.0% over the past year, against +12.4% for the S&P 500.
How many SOLV shares are sold short?
5M shares were sold short at the latest FINRA report, 4.26% of the float, or 4.6 days of average trading volume.
Who are Solventum's competitors?
Companies most similar to Solventum by business, industry and size include BAX, RMD, TFX, BSX, MDLN.
See a number that looks wrong?